Search
for
Sort by
Research 241–270 of 773
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- New Modalities in the Treatment of Refractory Alopecia Areata
- mTOR signaling in hair follicle and hair diseases: recent progress
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- Alopecia Areata: An Updated Review for 2023
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Stem cell-based therapies for alopecia areata: a narrative review
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice
- Targeted immunotherapy for hair regrowth and regeneration
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Research Progress in Chronic Autoimmune Urticaria
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- Hair Growth Effect of DN106212 in C57BL/6 Mouse and Its Network Pharmacological Mechanism of Action
- Ritlecitinib in severe alopecia areata: a profile of its use
- New therapies for alopecia areata
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism